Cargando…

The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer

Metastatic prostate cancer, which shows progression despite castration testosterone levels, was previously defined as hormone-refractory. This definition has recently been changed to the one presently used – castrate-resistant prostate cancer. Numerous fundamental studies have provided evidence that...

Descripción completa

Detalles Bibliográficos
Autores principales:	Milecki, Tomasz, Antczak, Andrzej, Kwias, Zbigniew, Milecki, Piotr
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4068814/ https://www.ncbi.nlm.nih.gov/pubmed/24966789 http://dx.doi.org/10.5114/wo.2014.42723

Ejemplares similares

Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?
por: Milecki, Tomasz, et al.
Publicado: (2015)

Radiotherapy combined with hormonal therapy in prostate cancer: the state of the art
por: Milecki, Piotr, et al.
Publicado: (2010)

What is the possible role of PSA doubling time (PSADT) and PSA velocity (PSAV) in the decision-making process to initiate salvage radiotherapy following radical prostatectomy in patients with prostate cancer?
por: Milecki, Piotr, et al.
Publicado: (2011)

Benefit of Whole Pelvic Radiotherapy Combined with Neoadjuvant Androgen Deprivation for the High-Risk Prostate Cancer
por: Milecki, Piotr, et al.
Publicado: (2009)

Development of castration resistance in prostate cancer patients treated with luteinizing hormone-releasing hormone analogues (LHRHa): results of the ANARESISTANCE study
por: Angulo, J. C., et al.
Publicado: (2022)

Characterization of Luteinizing Hormone and Luteinizing Hormone Receptor and Their Indispensable Role in the Ovulatory Process of the Medaka
por: Ogiwara, Katsueki, et al.
Publicado: (2013)

Polish Medical Students’ Knowledge Regarding Human Papillomavirus’s Ways of Transmission, Risk of Cancer Development and Vaccination, and Their Intention to Recommend Vaccination
por: Milecki, Tomasz, et al.
Publicado: (2021)

Failure to achieve castrate level of serum testosterone during luteinizing hormone-releasing hormone agonist therapy in a patient with prostate cancer
por: Koh, Yoko, et al.
Publicado: (2020)

Incidence Rate of Injection-Site Granulomas Resulting from the Administration of Luteinizing Hormone-Releasing Hormone Analogues for the Treatment of Prostatic Cancer
por: Shiota, Masaki, et al.
Publicado: (2007)

Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
por: Kaufmann, M.
Publicado: (1998)

Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
por: Jonat, W.
Publicado: (1998)

Effectiveness of three different luteinizing hormone-releasing hormone agonists in the chemical castration of patients with prostate cancer: Goserelin versus triptorelin versus leuprolide
por: Shim, Myungsun, et al.
Publicado: (2019)

An Unusual Prostate-Specific Antigen Decrease in an Advanced Castration-Resistant Prostate Cancer Patient with Intracerebral Hemorrhage Subsequently Treated with Luteinizing Hormone-Releasing Hormone Antagonist
por: Izumi, Kouji, et al.
Publicado: (2013)

Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats.
por: Maynard, P. V., et al.
Publicado: (1979)

Bilateral injection-site granuloma by subcutaneous administration of luteinizing hormone-releasing hormone analogue: a case report
por: Kitazawa, Riko, et al.
Publicado: (2009)

Reasons behind the Delayed Diagnosis of Testicular Cancer: A Retrospective Analysis
por: Cieślikowski, Wojciech A., et al.
Publicado: (2023)

Urology resident training in laparoscopic surgery – results of the first national survey in Poland
por: Brzoszczyk, Bartosz, et al.
Publicado: (2019)

Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration
por: Morote, Juan, et al.
Publicado: (2020)

Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review
por: Zhang, Xianlu, et al.
Publicado: (2023)

Luteinizing Hormone-Releasing Hormone Distribution in the Anterior Hypothalamus of the Female Rats
por: Castañeyra-Ruiz, Leandro, et al.
Publicado: (2013)

Progression of Intracranial Meningioma during Luteinizing Hormone-Releasing Hormone Agonist Treatment for Prostate Cancer: Case Report
por: ANDA, Takeo, et al.
Publicado: (2014)

A conjugate of methotrexate and an analog of luteinizing hormone releasing hormone shows increased efficacy against prostate cancer
por: Zhu, Shengsheng, et al.
Publicado: (2016)

Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000)

Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients
por: Morote, Juan, et al.
Publicado: (2017)

Attitudes about Testicular Self-Examination among Polish Males
por: Milecki, Tomasz, et al.
Publicado: (2021)

Linear Drive Based on Silicon/Ethanol Composite
por: Kapłon, Tomasz, et al.
Publicado: (2021)

Research on the Use of Silicon-Ethanol Composite in Actuators
por: Kapłon, Tomasz, et al.
Publicado: (2022)

Topographical localization of the receptors for luteinizing hormone- releasing hormone on the surface of dissociated pituitary cells
Publicado: (1977)

Identification of RCC Subtype-Specific microRNAs–Meta-Analysis of High-Throughput RCC Tumor microRNA Expression Data
por: Kajdasz, Arkadiusz, et al.
Publicado: (2021)

Transformation of a prostatic adenocarcinoma into squamous cell carcinoma after luteinizing hormone-releasing hormone (LHRH) agonist and radiotherapy treatment
por: Ichaoui, Hamza, et al.
Publicado: (2019)

Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer
por: Sugino, Fumiya, et al.
Publicado: (2023)

The enigma of the gonadotropin-releasing hormone pulse frequency governing individual secretion of luteinizing hormone and follicle-stimulating hormone
por: Lambalk, Cornelis B.
Publicado: (2023)

Effects of a luteinizing hormone-releasing hormone agonist on cognitive, sexual, and hormonal functions in patients with prostate cancer: relationship with testicular and adrenal androgen levels
por: Okamoto, Kohei, et al.
Publicado: (2015)

Effects of luteinizing hormone-releasing hormone and arginine-vasotocin on the sperm-release response of Günther's Toadlet, Pseudophryne guentheri
por: Silla, Aimee J
Publicado: (2010)

Association of the genetic variants of luteinizing hormone, luteinizing hormone receptor and polycystic ovary syndrome
por: Liu, Nana, et al.
Publicado: (2012)

Application of luteinizing hormone-releasing hormone–ferrosoferric oxide nanoparticles in targeted imaging of breast tumors
por: Nian, Di, et al.
Publicado: (2019)

Detection of urinary luteinizing hormone in Japanese black cows after administration of gonadotropin-releasing hormone
por: MIYAZAKI, Tamako, et al.
Publicado: (2021)

Unusual side effect from a luteinizing hormone-releasing hormone agonist, leuprorelin, in the treatment of prostate cancer: a case report
por: Chang, John I-Chiang, et al.
Publicado: (2016)

Luteinizing Hormone Levels Relate to the Unfavorable Pathology of Prostate Cancer
por: Choi, Se Young, et al.
Publicado: (2020)

Hormonal therapy and chemotherapy in hormone-naive and castration resistant prostate cancer
por: Recine, Federica, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_ovluskn3t3utnha47biqdb52aa